6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
observed	VBN	observed	observed	observ	N	O
across	IN	across	across	across	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
in	IN	in	in	in	N	O
type	NN	type	type	type	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
as	IN	as	a	as	N	O
those	DT	those	those	those	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table1	NNP	table1	table1	table1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
acute	JJ	acute	acute	acut	N	O
reactions	NNS	reactions	reaction	reaction	N	O
requiring	VBG	requiring	requiring	requir	N	O
intervention	NN	intervention	intervention	intervent	N	O
were	VBD	were	were	were	N	O
managed	VBN	managed	managed	manag	N	O
by	IN	by	by	by	N	O
either	DT	either	either	either	N	O
temporarily	RB	temporarily	temporarily	temporarili	N	O
interrupting	NN	interrupting	interrupting	interrupt	N	O
or	CC	or	or	or	N	O
discontinuing	VBG	discontinuing	discontinuing	discontinu	N	O
infusion	NN	infusion	infusion	infus	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
administering	VBG	administering	administering	administ	N	O
additional	JJ	additional	additional	addit	N	O
antihistamine	NN	antihistamine	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
placebo	FW	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
pyrexia	JJ	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
BioMarin	NNP	biomarin	biomarin	biomarin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
866	CD	866	866	866	N	O
-	:	-	-	-	N	O
906	CD	906	906	906	N	O
-	:	-	-	-	N	O
6100	CD	6100	6100	6100	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

A	DT	a	a	a	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
176	CD	176	176	176	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MPS	NNP	mps	mp	mp	N	O
IVA	NNP	iva	iva	iva	N	O
,	,	,	,	,	N	O
ages	VBZ	ages	age	age	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
57	CD	57	57	57	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
half	NN	half	half	half	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
49%	CD	49%	49%	49%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
176	CD	176	176	176	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
65%	CD	65%	65%	65%	N	O
were	VBD	were	were	were	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
23%	CD	23%	23%	23%	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
Black	NNP	black	black	black	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10%	CD	10%	10%	10%	N	O
Other	JJ	other	other	other	N	O
race	NN	race	race	race	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
78%	CD	78%	78%	78%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
Hispanic	NN	hispanic	hispanic	hispan	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
three	CD	three	three	three	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
:	:	:	:	:	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
week	NN	week	week	week	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
58	CD	58	58	58	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
59	CD	59	59	59	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
59	CD	59	59	59	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
each	DT	each	each	each	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
week	NN	week	week	week	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
That	WDT	that	that	that	N	O
Occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trial	JJ	trial	trial	trial	N	O
in	IN	in	in	in	N	O
At	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
Once	NNP	once	once	onc	N	O
Per	NNP	per	per	per	N	O
Week	NNP	week	week	week	N	O
Group	NNP	group	group	group	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Group	NNP	group	group	group	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
week	NN	week	week	week	N	O
Placebo	NN	placebo	placebo	placebo	N	O

N	NNP	n	n	n	N	O
58	CD	58	58	58	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
N	NNP	n	n	n	N	O
59	CD	59	59	59	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
33%	CD	33%	33%	33%	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
31%	CD	31%	31%	31%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
21%	CD	21%	21%	21%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
)	)	)	)	)	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
10.3%	CD	10.3%	10.3%	10.3%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
)	)	)	)	)	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
10.3%	CD	10.3%	10.3%	10.3%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O
)	)	)	)	)	N	O

Extension	NN	extension	extension	extens	N	O
Trial	NN	trial	trial	trial	N	O

An	DT	an	an	an	N	O

open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
173	CD	173	173	173	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
completed	VBD	completed	completed	complet	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
[	NN	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
new	JJ	new	new	new	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
week	NN	week	week	week	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
developed	VBD	developed	developed	develop	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
by	IN	by	by	by	N	O
Week	JJ	week	week	week	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Anti	NNP	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
were	VBD	were	were	were	N	O
sustained	VBN	sustained	sustained	sustain	N	O
or	CC	or	or	or	N	O
increased	VBN	increased	increased	increas	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
,	,	,	,	,	N	O
associations	NNS	associations	association	associ	N	O
between	IN	between	between	between	N	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
and	CC	and	and	and	N	O
reductions	NNS	reductions	reduction	reduct	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
effect	NN	effect	effect	effect	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
2	CD	2	2	2	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
once	RB	once	once	onc	N	O
per	IN	per	per	per	N	O
week	NN	week	week	week	N	O
tested	VBN	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
capable	JJ	capable	capable	capabl	N	O
of	IN	of	of	of	N	O
inhibiting	VBG	inhibiting	inhibiting	inhibit	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
from	IN	from	from	from	N	O
binding	VBG	binding	binding	bind	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
mannose	JJ	mannose	mannose	mannos	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
phosphate	NN	phosphate	phosphate	phosphat	Y	O
receptor	NN	receptor	receptor	receptor	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
once	RB	once	once	onc	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Binding	VBG	binding	binding	bind	N	O
to	TO	to	to	to	N	O
this	DT	this	this	thi	N	O
receptor	NN	receptor	receptor	receptor	N	O
is	VBZ	is	is	is	N	O
required	VBN	required	required	requir	N	O
for	IN	for	for	for	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
into	IN	into	into	into	N	O
cells	NNS	cells	cell	cell	N	O
where	WRB	where	where	where	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
active	JJ	active	active	activ	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
determined	VBN	determined	determined	determin	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
association	NN	association	association	associ	N	O
between	IN	between	between	between	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
titer	NN	titer	titer	titer	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
effect	NN	effect	effect	effect	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

Assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
Vimizim	VB	vimizim	vimizim	vimizim	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
presenting	VBG	presenting	presenting	present	N	O
as	IN	as	a	as	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
retching	NN	retching	retching	retch	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
during	IN	during	during	dure	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
infusions	NNS	infusions	infusion	infus	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
observe	JJ	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
administration	NN	administration	administration	administr	N	O
and	CC	and	and	and	N	O
be	VB	be	be	be	N	O
prepared	VBN	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
.	.	.	.	.	N	O

Inform	NNP	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
them	PRP	them	them	them	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
symptoms	VB	symptoms	symptom	symptom	N	O
occur	NN	occur	occur	occur	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
illness	NN	illness	illness	ill	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
acute	JJ	acute	acute	acut	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
compromise	NN	compromise	compromise	compromis	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VBP	require	require	requir	N	O
additional	JJ	additional	additional	addit	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
presenting	VBG	presenting	presenting	present	N	O
as	IN	as	a	as	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
during	IN	during	during	dure	N	O
infusions	NNS	infusions	infusion	infus	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
observe	JJ	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
administration	NN	administration	administration	administr	N	O
and	CC	and	and	and	N	O
be	VB	be	be	be	N	O
prepared	VBN	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
.	.	.	.	.	N	O

Inform	NNP	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
them	PRP	them	them	them	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
symptoms	VB	symptoms	symptom	symptom	N	O
occur	NN	occur	occur	occur	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
illness	NN	illness	illness	ill	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
acute	JJ	acute	acute	acut	N	O
exacerbation	NN	exacerbation	exacerbation	exacerb	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
compromise	NN	compromise	compromise	compromis	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VBP	require	require	requir	N	O
additional	JJ	additional	additional	addit	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anaphylaxis	NNS	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
immediately	RB	immediately	immediately	immedi	N	O
stop	VB	stop	stop	stop	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Complications	NNP	complications	complication	complic	N	I-AdverseReaction
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
febrile	NN	febrile	febrile	febril	N	O
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
illness	NN	illness	illness	ill	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
complications	NNS	complications	complication	complic	N	O
from	IN	from	from	from	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Careful	JJ	careful	careful	care	N	O
consideration	NN	consideration	consideration	consider	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
clinical	JJ	clinical	clinical	clinic	N	O
status	NN	status	status	statu	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
delaying	VBG	delaying	delaying	delay	N	O
the	DT	the	the	the	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
infusion	NN	infusion	infusion	infus	Y	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
premarketing	VBG	premarketing	premarketing	premarket	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
18	CD	18	18	18	N	O
of	IN	of	of	of	N	O
235	CD	235	235	235	N	O
(	(	(	(	(	N	O
7.7%	CD	7.7%	7.7%	7.7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
experienced	VBD	experienced	experienced	experienc	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
18	CD	18	18	18	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
26	CD	26	26	26	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
during	IN	during	during	dure	N	O
infusion	NN	infusion	infusion	infus	Y	O
with	IN	with	with	with	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
including	VBG	including	including	includ	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
retching	NN	retching	retching	retch	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
conjunction	NN	conjunction	conjunction	conjunct	N	O
with	IN	with	with	with	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
as	RB	as	a	as	N	O
early	RB	early	early	earli	N	O
as	IN	as	a	as	N	O
30	CD	30	30	30	N	O
minutes	NNS	minutes	minute	minut	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
three	CD	three	three	three	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Anaphylaxis	RB	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
as	IN	as	a	as	N	O
late	JJ	late	late	late	N	O
into	IN	into	into	into	N	O
treatment	NN	treatment	treatment	treatment	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
47	CD	47	47	47	N	O
th	JJ	th	th	th	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
,	,	,	,	,	N	O
44	CD	44	44	44	N	O
of	IN	of	of	of	N	O
235	CD	235	235	235	N	O
(	(	(	(	(	N	O
18.7%	CD	18.7%	18.7%	18.7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
as	RB	as	a	as	N	O
early	RB	early	early	earli	N	O
as	IN	as	a	as	N	O
30	CD	30	30	30	N	O
minutes	NNS	minutes	minute	minut	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
but	CC	but	but	but	N	O
as	RB	as	a	as	N	O
late	RB	late	late	late	N	O
as	IN	as	a	as	N	O
six	CD	six	six	six	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Frequent	NNP	frequent	frequent	frequent	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
included	VBD	included	included	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
.	.	.	.	.	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
readily	RB	readily	readily	readili	N	O
available	JJ	available	available	avail	N	O
when	WRB	when	when	when	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

Observe	NN	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
,	,	,	,	,	N	O
taking	VBG	taking	taking	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
premarketing	VBG	premarketing	premarketing	premarket	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Inform	NNP	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
instruct	VB	instruct	instruct	instruct	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
occur	VBP	occur	occur	occur	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
administer	NN	administer	administer	administ	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reaction	NN	reaction	reaction	reaction	N	O
and	CC	and	and	and	N	O
include	VBP	include	include	includ	N	O
slowing	VBG	slowing	slowing	slow	N	O
or	CC	or	or	or	N	O
temporary	JJ	temporary	temporary	temporari	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
additional	JJ	additional	additional	addit	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
for	IN	for	for	for	N	O
mild	JJ	mild	mild	mild	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
immediately	RB	immediately	immediately	immedi	N	O
stop	VB	stop	stop	stop	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
re	NN	re	re	re	N	O
-	:	-	-	-	N	O
administering	VBG	administering	administering	administ	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
following	VBG	following	following	follow	N	O
a	DT	a	a	a	N	O
severe	JJ	severe	severe	sever	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Acute	NNP	acute	acute	acut	N	O
Respiratory	NNP	respiratory	respiratory	respiratori	N	O
Complications	NNP	complications	complication	complic	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
febrile	NN	febrile	febrile	febril	N	O
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
illness	NN	illness	illness	ill	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
infusion	NN	infusion	infusion	infus	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
complications	NNS	complications	complication	complic	N	O
from	IN	from	from	from	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Careful	JJ	careful	careful	care	N	O
consideration	NN	consideration	consideration	consider	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
clinical	JJ	clinical	clinical	clinic	N	O
status	NN	status	status	statu	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
delaying	VBG	delaying	delaying	delay	N	O
the	DT	the	the	the	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Sleep	JJ	sleep	sleep	sleep	N	O
apnea	NN	apnea	apnea	apnea	Y	O
is	VBZ	is	is	is	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
MPS	NNP	mps	mp	mp	N	O
IVA	NNP	iva	iva	iva	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
airway	JJ	airway	airway	airway	N	O
patency	NN	patency	patency	patenc	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
supplemental	JJ	supplemental	supplemental	supplement	N	O
oxygen	NN	oxygen	oxygen	oxygen	N	O
or	CC	or	or	or	N	O
continuous	JJ	continuous	continuous	continu	N	O
positive	JJ	positive	positive	posit	N	O
airway	NN	airway	airway	airway	N	O
pressure	NN	pressure	pressure	pressur	N	O
(	(	(	(	(	N	O
CPAP	NNP	cpap	cpap	cpap	Y	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
sleep	NN	sleep	sleep	sleep	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
these	DT	these	these	these	N	O
treatments	NNS	treatments	treatment	treatment	N	O
readily	RB	readily	readily	readili	N	O
available	JJ	available	available	avail	N	O
during	IN	during	during	dure	N	O
infusion	NN	infusion	infusion	infus	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
acute	JJ	acute	acute	acut	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
extreme	JJ	extreme	extreme	extrem	N	O
drowsiness	NN	drowsiness	drowsiness	drowsi	Y	O
sleep	NN	sleep	sleep	sleep	N	O
induced	VBN	induced	induced	induc	N	O
by	IN	by	by	by	N	O
antihistamine	NN	antihistamine	antihistamine	antihistamin	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Spinal	NNP	spinal	spinal	spinal	N	O
or	CC	or	or	or	N	O
Cervical	NNP	cervical	cervical	cervic	N	O
Cord	NNP	cord	cord	cord	N	O
Compression	NNP	compression	compression	compress	N	O

Spinal	NNP	spinal	spinal	spinal	N	O
or	CC	or	or	or	N	O
cervical	JJ	cervical	cervical	cervic	N	O
cord	NN	cord	cord	cord	N	O
compression	NN	compression	compression	compress	N	O
(	(	(	(	(	N	O
SCC	NNP	scc	scc	scc	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
known	JJ	known	known	known	N	O
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	O
complication	NN	complication	complication	complic	N	O
of	IN	of	of	of	N	O
MPS	NNP	mps	mp	mp	N	O
IVA	NNP	iva	iva	iva	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
as	IN	as	a	as	N	O
part	NN	part	part	part	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
natural	JJ	natural	natural	natur	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
SCC	NNP	scc	scc	scc	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
both	DT	both	both	both	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Vimizim	NNP	vimizim	vimizim	vimizim	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MPS	NNP	mps	mp	mp	N	O
IVA	NNP	iva	iva	iva	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
SCC	NNP	scc	scc	scc	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
back	RB	back	back	back	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
paralysis	NN	paralysis	paralysis	paralysi	Y	O
of	IN	of	of	of	N	O
limbs	NNS	limbs	limb	limb	N	O
below	IN	below	below	below	N	O
the	DT	the	the	the	N	O
level	NN	level	level	level	N	O
of	IN	of	of	of	N	O
compression	NN	compression	compression	compress	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	O
and	CC	and	and	and	N	O
fecal	JJ	fecal	fecal	fecal	N	O
incontinence	NN	incontinence	incontinence	incontin	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
given	VBN	given	given	given	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
clinical	JJ	clinical	clinical	clinic	N	O
care	NN	care	care	care	N	O
.	.	.	.	.	N	O

